In this work, the production of inhalable polymeric microparticles with modulable porosity is described. The starting polymeric material was the PHEA-g-RhB-g-PLA graft copolymer, which was suitably processed by spray drying (SD). Thanks to the addition of AB (weight percentage equal to 10 and 20 % with respect to the polymer) in the liquid feed, three biocompatible matrices were obtained with an increasing porosity in terms of pore volume (from 0.015 to 0.024 cc/g) and pore average diameter (from 1.942 to 3.060 nm), a decreasing tapped density values (from 0.75 to 0.50), and favorable aerosolization characteristics. These differences were high-lighted also by a significant increase in the release of Rapamycin from the sample which showed the higher porosity (31.0 wt% after 24 hrs incubation) than the sample with the lowest porosity (14.9 wt%) in simulated lung fluid.
Craparo, E.F., Cabibbo, M., Emanuele Drago, S., Casula, L., Lai, F., Cavallaro, G. (2022). Inhalable polymeric microparticles as pharmaceutical porous powder for drug administration. INTERNATIONAL JOURNAL OF PHARMACEUTICS, 628 [10.1016/j.ijpharm.2022.122325].
Inhalable polymeric microparticles as pharmaceutical porous powder for drug administration
Craparo, Emanuela FabiolaPrimo
;Cabibbo, Marta;Emanuele Drago, Salvatore;Cavallaro, Gennara
Ultimo
2022-10-15
Abstract
In this work, the production of inhalable polymeric microparticles with modulable porosity is described. The starting polymeric material was the PHEA-g-RhB-g-PLA graft copolymer, which was suitably processed by spray drying (SD). Thanks to the addition of AB (weight percentage equal to 10 and 20 % with respect to the polymer) in the liquid feed, three biocompatible matrices were obtained with an increasing porosity in terms of pore volume (from 0.015 to 0.024 cc/g) and pore average diameter (from 1.942 to 3.060 nm), a decreasing tapped density values (from 0.75 to 0.50), and favorable aerosolization characteristics. These differences were high-lighted also by a significant increase in the release of Rapamycin from the sample which showed the higher porosity (31.0 wt% after 24 hrs incubation) than the sample with the lowest porosity (14.9 wt%) in simulated lung fluid.File | Dimensione | Formato | |
---|---|---|---|
pubbl75_IntJPharm2022.pdf
Solo gestori archvio
Tipologia:
Versione Editoriale
Dimensione
5.28 MB
Formato
Adobe PDF
|
5.28 MB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.